{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T15:42:16Z","timestamp":1764603736463,"version":"3.37.3"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanopart Res"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1007\/s11051-020-05118-9","type":"journal-article","created":{"date-parts":[[2021,1,28]],"date-time":"2021-01-28T11:54:14Z","timestamp":1611834854000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Acetylcholinesterase inhibitors and nanoparticles on Alzheimer\u2019s disease: a review"],"prefix":"10.1007","volume":"23","author":[{"given":"Sara","family":"Silva","sequence":"first","affiliation":[]},{"given":"Ant\u00f3nio J.","family":"Almeida","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1283-1042","authenticated-orcid":false,"given":"Nuno","family":"Vale","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2021,1,6]]},"reference":[{"key":"5118_CR1","unstructured":"Alonso MJ, Couvreur P (2012) Chapter 1. historical view of the design and development of nanocarriers for overcoming biological barriers. In: nanostructured biomaterials for overcoming biological barriers. The Royal Society of Chemistry, pp 3\u201336"},{"key":"5118_CR2","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/ng1197-263","volume":"17","author":"KR Bales","year":"1997","unstructured":"Bales KR, Verina T, Dodel RC, du Y, Altstiel L, Bender M, Hyslop P, Johnstone EM, Little SP, Cummins DJ, Piccardo P, Ghetti B, Paul SM (1997) Lack of apolipoprotein E dramatically reduces amyloid \u03b2-peptide deposition. Nat Genet 17:263\u2013264. https:\/\/doi.org\/10.1038\/ng1197-263","journal-title":"Nat Genet"},{"key":"5118_CR3","doi-asserted-by":"publisher","first-page":"15233","DOI":"10.1073\/pnas.96.26.15233","volume":"96","author":"KR Bales","year":"1999","unstructured":"Bales KR, Verina T, Cummins DJ, du Y, Dodel RC, Saura J, Fishman CE, DeLong CA, Piccardo P, Petegnief V, Ghetti B, Paul SM (1999) Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer\u2019s disease. Proc Natl Acad Sci U S A 96:15233\u201315238. https:\/\/doi.org\/10.1073\/pnas.96.26.15233","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5118_CR4","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1517\/17425247.2012.673278","volume":"9","author":"L Battaglia","year":"2012","unstructured":"Battaglia L, Gallarate M (2012) Lipid nanoparticles: state of the art, new preparation methods and challenges in drug delivery. Expert Opin Drug Deliv 9:497\u2013508. https:\/\/doi.org\/10.1517\/17425247.2012.673278","journal-title":"Expert Opin Drug Deliv"},{"key":"5118_CR5","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s00702-016-1527-4","volume":"124","author":"I Baysal","year":"2017","unstructured":"Baysal I, Ucar G, Gultekinoglu M, Ulubayram K, Yabanoglu-Ciftci S (2017) Donepezil loaded PLGA-b-PEG nanoparticles: their ability to induce destabilization of amyloid fibrils and to cross blood brain barrier in vitro. J Neural Transm 124:33\u201345. https:\/\/doi.org\/10.1007\/s00702-016-1527-4","journal-title":"J Neural Transm"},{"key":"5118_CR6","doi-asserted-by":"publisher","first-page":"2688","DOI":"10.1039\/c6an00357e","volume":"141","author":"S Ben\u00edtez-Mart\u00ednez","year":"2016","unstructured":"Ben\u00edtez-Mart\u00ednez S, Caballero-D\u00edaz E, Valc\u00e1rcel M (2016) Development of a biosensing system for tacrine based on nitrogen-doped graphene quantum dots and acetylcholinesterase. Analyst 141:2688\u20132695. https:\/\/doi.org\/10.1039\/c6an00357e","journal-title":"Analyst"},{"key":"5118_CR7","doi-asserted-by":"publisher","first-page":"278","DOI":"10.3109\/03639045.2012.758130","volume":"40","author":"B Bhavna","year":"2014","unstructured":"Bhavna B, Shadab M, Ali M et al (2014) Preparation, characterization, in vivo biodistribution and pharmacokinetic studies of donepezil-loaded PLGA nanoparticles for brain targeting. Drug Dev Ind Pharm 40:278\u2013287. https:\/\/doi.org\/10.3109\/03639045.2012.758130","journal-title":"Drug Dev Ind Pharm"},{"key":"5118_CR8","doi-asserted-by":"publisher","unstructured":"Birks JS, Harvey RJ (2018) Donepezil for dementia due to Alzheimer\u2019s disease. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD001190.pub3","DOI":"10.1002\/14651858.CD001190.pub3"},{"key":"5118_CR9","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S0140-6736(06)69113-7","volume":"368","author":"K Blennow","year":"2006","unstructured":"Blennow K, de Leon MJ, Zetterberg H (2006) Alzheimer\u2019s disease. Lancet 368:387\u2013403. https:\/\/doi.org\/10.1016\/S0140-6736(06)69113-7","journal-title":"Lancet"},{"key":"5118_CR10","doi-asserted-by":"publisher","first-page":"247","DOI":"10.7861\/clinmedicine.16-3-247","volume":"16","author":"R Briggs","year":"2016","unstructured":"Briggs R, Kennelly SP, O\u2019Neill D (2016) Drug treatments in Alzheimer\u2019s disease. Clin Med (Northfield Il) 16:247\u2013253. https:\/\/doi.org\/10.7861\/clinmedicine.16-3-247","journal-title":"Clin Med (Northfield Il)"},{"key":"5118_CR11","doi-asserted-by":"publisher","first-page":"234","DOI":"10.2165\/00002512-199710030-00007","volume":"10","author":"HM Bryson","year":"1997","unstructured":"Bryson HM, Benfield P (1997) Donepezil. Drugs Aging 10:234\u2013239. https:\/\/doi.org\/10.2165\/00002512-199710030-00007","journal-title":"Drugs Aging"},{"key":"5118_CR12","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/s41583-019-0132-6","volume":"20","author":"DA Butterfield","year":"2019","unstructured":"Butterfield DA, Halliwell B (2019) Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease. Nat Rev Neurosci 20:148\u2013160. https:\/\/doi.org\/10.1038\/s41583-019-0132-6","journal-title":"Nat Rev Neurosci"},{"key":"5118_CR13","first-page":"215","volume-title":"Human physiology","author":"L Cole","year":"2016","unstructured":"Cole L, Kramer PR (2016) Alzheimer\u2019s disease. In: Human physiology. Elsevier, Biochemistry and Basic Medicine, pp 215\u2013217"},{"key":"5118_CR14","doi-asserted-by":"publisher","first-page":"323","DOI":"10.3109\/08982104.2014.899369","volume":"24","author":"G Corace","year":"2014","unstructured":"Corace G, Angeloni C, Malaguti M, Hrelia S, Stein PC, Brandl M, Gotti R, Luppi B (2014) Multifunctional liposomes for nasal delivery of the anti-Alzheimer drug tacrine hydrochloride. J Liposome Res 24:323\u2013335. https:\/\/doi.org\/10.3109\/08982104.2014.899369","journal-title":"J Liposome Res"},{"key":"5118_CR15","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1002\/mabi.200700165","volume":"8","author":"EF Craparo","year":"2008","unstructured":"Craparo EF, Pitarresi G, Bondi ML et al (2008) A nanoparticulate drug-delivery system for rivastigmine: physico-chemical and in vitro biological characterization. Macromol Biosci 8:247\u2013259. https:\/\/doi.org\/10.1002\/mabi.200700165","journal-title":"Macromol Biosci"},{"key":"5118_CR16","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1177\/106002809402800612","volume":"28","author":"ML Crismon","year":"1994","unstructured":"Crismon ML (1994) Tacrine: first drug approved for Alzheimer\u2019s disease. Ann Pharmacother 28:744\u2013751. https:\/\/doi.org\/10.1177\/106002809402800612","journal-title":"Ann Pharmacother"},{"key":"5118_CR17","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1080\/17425247.2016.1182485","volume":"13","author":"AA D\u2019souza","year":"2016","unstructured":"D\u2019souza AA, Shegokar R (2016) Polyethylene glycol (PEG): a versatile polymer for pharmaceutical applications. Expert Opin Drug Deliv 13:1257\u20131275. https:\/\/doi.org\/10.1080\/17425247.2016.1182485","journal-title":"Expert Opin Drug Deliv"},{"key":"5118_CR18","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1586\/14737175.5.5.563","volume":"5","author":"AK Desai","year":"2005","unstructured":"Desai AK, Grossberg GT (2005) Rivastigmine for Alzheimer\u2019s disease. Expert Rev Neurother 5:563\u2013580. https:\/\/doi.org\/10.1586\/14737175.5.5.563","journal-title":"Expert Rev Neurother"},{"key":"5118_CR19","first-page":"155","volume":"8","author":"A Dinesh Raja","year":"2012","unstructured":"Dinesh Raja A, Mohambed M, Joji S et al (2012) Design and evaluation of chitosan nanoparticles as novel drug carriers for the delivery of donepezil. Iran J Pharm Sci 8:155\u2013164","journal-title":"Iran J Pharm Sci"},{"key":"5118_CR20","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1111\/j.1749-6632.1991.tb00232.x","volume":"640","author":"A Enz","year":"1991","unstructured":"Enz A, Boddeke H, Gray J, Spiegel R (1991) Pharmacologic and clinicopharmacologic properties of SDZ ENA 713, a centrally selective acetylcholinesterase inhibitor. Ann N Y Acad Sci 640:272\u2013275. https:\/\/doi.org\/10.1111\/j.1749-6632.1991.tb00232.x","journal-title":"Ann N Y Acad Sci"},{"key":"5118_CR21","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.brainresbull.2018.10.009","volume":"143","author":"F Erd\u0151","year":"2018","unstructured":"Erd\u0151 F, Bors LA, Farkas D, Bajza \u00c1, Gizurarson S (2018) Evaluation of intranasal delivery route of drug administration for brain targeting. Brain Res Bull 143:155\u2013170. https:\/\/doi.org\/10.1016\/j.brainresbull.2018.10.009","journal-title":"Brain Res Bull"},{"key":"5118_CR22","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.ejps.2015.11.014","volume":"82","author":"M Eslami","year":"2016","unstructured":"Eslami M, Nikkhah SJ, Hashemianzadeh SM, Sajadi SAS (2016) The compatibility of tacrine molecule with poly(n-butylcyanoacrylate) and chitosan as efficient carriers for drug delivery: a molecular dynamics study. Eur J Pharm Sci 82:79\u201385. https:\/\/doi.org\/10.1016\/j.ejps.2015.11.014","journal-title":"Eur J Pharm Sci"},{"key":"5118_CR23","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.ejps.2012.04.013","volume":"47","author":"M Fazil","year":"2012","unstructured":"Fazil M, Md S, Haque S, Kumar M, Baboota S, Sahni J, Ali J (2012) Development and evaluation of rivastigmine loaded chitosan nanoparticles for brain targeting. Eur J Pharm Sci 47:6\u201315. https:\/\/doi.org\/10.1016\/j.ejps.2012.04.013","journal-title":"Eur J Pharm Sci"},{"key":"5118_CR24","doi-asserted-by":"publisher","first-page":"12076","DOI":"10.1039\/c5nr03474d","volume":"7","author":"C Fornaguera","year":"2015","unstructured":"Fornaguera C, Feiner-Gracia N, Calder\u00f3 G, Garc\u00eda-Celma MJ, Solans C (2015) Galantamine-loaded PLGA nanoparticles, from nano-emulsion templating, as novel advanced drug delivery systems to treat neurodegenerative diseases. Nanoscale 7:12076\u201312084. https:\/\/doi.org\/10.1039\/c5nr03474d","journal-title":"Nanoscale"},{"key":"5118_CR25","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1038\/clpt.1989.199","volume":"46","author":"DR Forsyth","year":"1989","unstructured":"Forsyth DR, Wilcock GK, Morgan RA, Truman CA, Ford JM, Roberts CJC (1989) Pharmacokinetics of tacrine hydrochloride in Alzheimer\u2019s disease. Clin Pharmacol Ther 46:634\u2013641. https:\/\/doi.org\/10.1038\/clpt.1989.199","journal-title":"Clin Pharmacol Ther"},{"key":"5118_CR26","doi-asserted-by":"publisher","first-page":"60","DOI":"10.2165\/00002512-199609010-00006","volume":"9","author":"B Fulton","year":"1996","unstructured":"Fulton B, Benfield P (1996) Galanthamine. Drugs Aging 9:60\u201365. https:\/\/doi.org\/10.2165\/00002512-199609010-00006","journal-title":"Drugs Aging"},{"key":"5118_CR27","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s00415-011-6145-3","volume":"259","author":"D Galimberti","year":"2012","unstructured":"Galimberti D, Scarpini E (2012) Progress in Alzheimer\u2019s disease. J Neurol 259:201\u2013211. https:\/\/doi.org\/10.1007\/s00415-011-6145-3","journal-title":"J Neurol"},{"key":"5118_CR28","doi-asserted-by":"publisher","first-page":"291","DOI":"10.3109\/1061186X.2011.654121","volume":"20","author":"A Grenha","year":"2012","unstructured":"Grenha A (2012) Chitosan nanoparticles: a survey of preparation methods. J Drug Target 20:291\u2013300. https:\/\/doi.org\/10.3109\/1061186X.2011.654121","journal-title":"J Drug Target"},{"key":"5118_CR29","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1083\/jcb.201709069","volume":"217","author":"DV Hansen","year":"2018","unstructured":"Hansen DV, Hanson JE, Sheng M (2018) Microglia in Alzheimer\u2019s disease. J Cell Biol 217:459\u2013472. https:\/\/doi.org\/10.1083\/jcb.201709069","journal-title":"J Cell Biol"},{"key":"5118_CR30","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1126\/science.1566067","volume":"256","author":"J Hardy","year":"1992","unstructured":"Hardy J, Higgins G (1992) Alzheimer\u2019s disease: the amyloid cascade hypothesis. Science (80-) 256:184\u2013185. https:\/\/doi.org\/10.1126\/science.1566067","journal-title":"Science (80-)"},{"key":"5118_CR31","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.colsurfa.2015.04.006","volume":"482","author":"S Hassani","year":"2015","unstructured":"Hassani S, Laouini A, Fessi H, Charcosset C (2015) Preparation of chitosan-TPP nanoparticles using microengineered membranes - effect of parameters and encapsulation of tacrine. Colloids Surfaces A Physicochem Eng Asp 482:34\u201343. https:\/\/doi.org\/10.1016\/j.colsurfa.2015.04.006","journal-title":"Colloids Surfaces A Physicochem Eng Asp"},{"key":"5118_CR32","doi-asserted-by":"publisher","first-page":"25","DOI":"10.22037\/icnj.v3i1.12358","volume":"3","author":"G Hassanzadeh","year":"2016","unstructured":"Hassanzadeh G, Fallahi Z, Khanmohammadi M, Elmizadeh H (2016) Effect of magnetic tacrine-loaded chitosan nanoparticles on spatial learning, memory, amyloid precursor protein and seladin-1 expression in the hippocampus of streptozotocin-exposed rats. Int Clin Neurosci J 3:25\u201331. https:\/\/doi.org\/10.22037\/icnj.v3i1.12358","journal-title":"Int Clin Neurosci J"},{"key":"5118_CR33","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/S1474-4422(15)70016-5","volume":"14","author":"MT Heneka","year":"2015","unstructured":"Heneka MT, Carson MJ, El Khoury J et al (2015) Neuroinflammation in Alzheimer\u2019s disease. Lancet Neurol 14:388\u2013405. https:\/\/doi.org\/10.1016\/S1474-4422(15)70016-5","journal-title":"Lancet Neurol"},{"key":"5118_CR34","doi-asserted-by":"publisher","first-page":"393","DOI":"10.2147\/IJN.S39232","volume":"8","author":"MF Ismail","year":"2013","unstructured":"Ismail MF, Elmeshad AN, Salem NAH (2013) Potential therapeutic effect of nanobased formulation of rivastigmine on rat model of Alzheimer\u2019s disease. Int J Nanomedicine 8:393\u2013406. https:\/\/doi.org\/10.2147\/IJN.S39232","journal-title":"Int J Nanomedicine"},{"key":"5118_CR35","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1517\/13543784.9.6.1397","volume":"9","author":"KK Jain","year":"2000","unstructured":"Jain KK (2000) Evaluation of memantine for neuroprotection in dementia. Expert Opin Investig Drugs 9:1397\u20131406. https:\/\/doi.org\/10.1517\/13543784.9.6.1397","journal-title":"Expert Opin Investig Drugs"},{"key":"5118_CR36","doi-asserted-by":"publisher","first-page":"465","DOI":"10.2165\/00002512-200320060-00005","volume":"20","author":"B Jarvis","year":"2003","unstructured":"Jarvis B, Figgitt DP (2003) Memantine. Drugs Aging 20:465\u2013476. https:\/\/doi.org\/10.2165\/00002512-200320060-00005","journal-title":"Drugs Aging"},{"key":"5118_CR37","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1097\/WAD.0b013e318157205b","volume":"22","author":"VV Jogani","year":"2008","unstructured":"Jogani VV, Shah PJ, Mishra P, Mishra AK, Misra AR (2008) Intranasal mucoadhesive microemulsion of tacrine to improve brain targeting. Alzheimer Dis Assoc Disord 22:116\u2013124. https:\/\/doi.org\/10.1097\/WAD.0b013e318157205b","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"5118_CR38","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.ejpb.2010.07.007","volume":"76","author":"SA Joshi","year":"2010","unstructured":"Joshi SA, Chavhan SS, Sawant KK (2010) Rivastigmine-loaded PLGA and PBCA nanoparticles: preparation, optimization, characterization, in vitro and pharmacodynamic studies. Eur J Pharm Biopharm 76:189\u2013199. https:\/\/doi.org\/10.1016\/j.ejpb.2010.07.007","journal-title":"Eur J Pharm Biopharm"},{"key":"5118_CR39","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1080\/03639045.2016.1275668","volume":"43","author":"M Karimzadeh","year":"2017","unstructured":"Karimzadeh M, Rashidi L, Ganji F (2017) Mesoporous silica nanoparticles for efficient rivastigmine hydrogen tartrate delivery into SY5Y cells. Drug Dev Ind Pharm 43:628\u2013636. https:\/\/doi.org\/10.1080\/03639045.2016.1275668","journal-title":"Drug Dev Ind Pharm"},{"key":"5118_CR40","doi-asserted-by":"publisher","unstructured":"Kawashima K, Sato A, Yoshizawa M, et al (1994) Effects of the centrally acting cholinesterase inhibitors tetrahydroaminoacridine and E2020 on the basal concentration of extracellular acetylcholine in the hippocampus of freely moving rats. Naunyn Schmiedebergs Arch Pharmacol 350:523\u2013528. https:\/\/doi.org\/10.1007\/BF00173022","DOI":"10.1007\/BF00173022"},{"key":"5118_CR41","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1021\/acschemneuro.9b00343","volume":"10","author":"KV Krishna","year":"2019","unstructured":"Krishna KV, Wadhwa G, Alexander A, Kanojia N, Saha RN, Kukreti R, Singhvi G, Dubey SK (2019) Design and biological evaluation of lipoprotein-based donepezil nanocarrier for enhanced brain uptake through oral delivery. ACS Chem Neurosci 10:4124\u20134135. https:\/\/doi.org\/10.1021\/acschemneuro.9b00343","journal-title":"ACS Chem Neurosci"},{"key":"5118_CR42","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/ene.13439","volume":"25","author":"CA Lane","year":"2018","unstructured":"Lane CA, Hardy J, Schott JM (2018) Alzheimer\u2019s disease. Eur J Neurol 25:59\u201370. https:\/\/doi.org\/10.1111\/ene.13439","journal-title":"Eur J Neurol"},{"key":"5118_CR43","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.ijpharm.2015.03.001","volume":"485","author":"S Laserra","year":"2015","unstructured":"Laserra S, Basit A, Sozio P, Marinelli L, Fornasari E, Cacciatore I, Ciulla M, T\u00fcrkez H, Geyikoglu F, di Stefano A (2015) Solid lipid nanoparticles loaded with lipoyl-memantine codrug: preparation and characterization. Int J Pharm 485:183\u2013191. https:\/\/doi.org\/10.1016\/j.ijpharm.2015.03.001","journal-title":"Int J Pharm"},{"key":"5118_CR44","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1080\/026520499288663","volume":"16","author":"J-H Lee","year":"1999","unstructured":"Lee J-H, Park H-KC TG (1999) Development of oral drug delivery system using floating microspheres. J Microencapsul 16:715\u2013729. https:\/\/doi.org\/10.1080\/026520499288663","journal-title":"J Microencapsul"},{"key":"5118_CR45","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.ejps.2011.10.002","volume":"44","author":"B Luppi","year":"2011","unstructured":"Luppi B, Bigucci F, Corace G, Delucca A, Cerchiara T, Sorrenti M, Catenacci L, di Pietra AM, Zecchi V (2011) Albumin nanoparticles carrying cyclodextrins for nasal delivery of the anti-Alzheimer drug tacrine. Eur J Pharm Sci 44:559\u2013565. https:\/\/doi.org\/10.1016\/j.ejps.2011.10.002","journal-title":"Eur J Pharm Sci"},{"key":"5118_CR46","doi-asserted-by":"publisher","first-page":"449","DOI":"10.2165\/00003088-199528060-00003","volume":"28","author":"S Madden","year":"1995","unstructured":"Madden S, Spaldin V, Park BK (1995) Clinical pharmacokinetics of tacrine. Clin Pharmacokinet 28:449\u2013457. https:\/\/doi.org\/10.2165\/00003088-199528060-00003","journal-title":"Clin Pharmacokinet"},{"key":"5118_CR47","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1080\/08982104.2017.1349143","volume":"28","author":"F Malekpour-Galogahi","year":"2018","unstructured":"Malekpour-Galogahi F, Hatamian-Zarmi A, Ganji F, Ebrahimi-Hosseinzadeh B, Nojoki F, Sahraeian R, Mokhtari-Hosseini ZB (2018) Preparation and optimization of rivastigmine-loaded tocopherol succinate-based solid lipid nanoparticles. J Liposome Res 28:226\u2013235. https:\/\/doi.org\/10.1080\/08982104.2017.1349143","journal-title":"J Liposome Res"},{"key":"5118_CR48","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1080\/14740338.2018.1524870","volume":"17","author":"S Matsunaga","year":"2018","unstructured":"Matsunaga S, Kishi T, Nomura I, Sakuma K, Okuya M, Ikuta T, Iwata N (2018) The efficacy and safety of memantine for the treatment of Alzheimer\u2019s disease. Expert Opin Drug Saf 17:1053\u20131061. https:\/\/doi.org\/10.1080\/14740338.2018.1524870","journal-title":"Expert Opin Drug Saf"},{"key":"5118_CR49","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.colsurfb.2019.02.007","volume":"177","author":"IT Mendes","year":"2019","unstructured":"Mendes IT, Ruela ALM, Carvalho FC, Freitas JTJ, Bonfilio R, Pereira GR (2019) Development and characterization of nanostructured lipid carrier-based gels for the transdermal delivery of donepezil. Colloids Surf B: Biointerfaces 177:274\u2013281. https:\/\/doi.org\/10.1016\/j.colsurfb.2019.02.007","journal-title":"Colloids Surf B: Biointerfaces"},{"key":"5118_CR50","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.3109\/10717544.2015.1089956","volume":"23","author":"S Misra","year":"2016","unstructured":"Misra S, Chopra K, Sinha VR, Medhi B (2016a) Galantamine-loaded solid\u2013lipid nanoparticles for enhanced brain delivery: preparation, characterization, in vitro and in vivo evaluations. Drug Deliv 23:1434\u20131443. https:\/\/doi.org\/10.3109\/10717544.2015.1089956","journal-title":"Drug Deliv"},{"key":"5118_CR51","doi-asserted-by":"publisher","first-page":"629","DOI":"10.2217\/rme-2016-0032","volume":"11","author":"S Misra","year":"2016","unstructured":"Misra S, Chopra K, Saikia UN, Sinha VR, Sehgal R, Modi M, Medhi B (2016b) Effect of mesenchymal stem cells and galantamine nanoparticles in rat model of Alzheimer\u2019s disease. Regen Med 11:629\u2013646. https:\/\/doi.org\/10.2217\/rme-2016-0032","journal-title":"Regen Med"},{"key":"5118_CR52","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.ijpharm.2013.03.037","volume":"448","author":"MS Mufamadi","year":"2013","unstructured":"Mufamadi MS, Choonara YE, Kumar P, Modi G, Naidoo D, van Vuuren S, Ndesendo VMK, Toit LC, Iyuke SE, Pillay V (2013) Ligand-functionalized nanoliposomes for targeted delivery of galantamine. Int J Pharm 448:267\u2013281. https:\/\/doi.org\/10.1016\/j.ijpharm.2013.03.037","journal-title":"Int J Pharm"},{"key":"5118_CR53","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ijbiomac.2013.04.024","volume":"59","author":"K Nagpal","year":"2013","unstructured":"Nagpal K, Singh SK, Mishra DN (2013) Optimization of brain targeted chitosan nanoparticles of rivastigmine for improved efficacy and safety. Int J Biol Macromol 59:72\u201383. https:\/\/doi.org\/10.1016\/j.ijbiomac.2013.04.024","journal-title":"Int J Biol Macromol"},{"key":"5118_CR54","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s40262-013-0038-9","volume":"52","author":"M Noetzli","year":"2013","unstructured":"Noetzli M, Eap CB (2013) Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer\u2019s disease. Clin Pharmacokinet 52:225\u2013241. https:\/\/doi.org\/10.1007\/s40262-013-0038-9","journal-title":"Clin Pharmacokinet"},{"key":"5118_CR55","doi-asserted-by":"publisher","first-page":"465","DOI":"10.2165\/00002018-199819060-00004","volume":"19","author":"A Nordberg","year":"1998","unstructured":"Nordberg A, Svensson A-L (1998) Cholinesterase inhibitors in the treatment of Alzheimer\u2019s disease. Drug Saf 19:465\u2013480. https:\/\/doi.org\/10.2165\/00002018-199819060-00004","journal-title":"Drug Saf"},{"key":"5118_CR56","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1002\/j.1552-4604.1993.tb01945.x","volume":"33","author":"A Ohnishi","year":"1993","unstructured":"Ohnishi A, Mihara M, Kamakura H, Tomono Y, Hasegawa J, Yamazaki K, Morishita N, Tanaka T (1993) Comparison of the pharmacokinetics of E2020, a new compound for Alzheimer\u2019s disease, in healthy young and elderly subjects. J Clin Pharmacol 33:1086\u20131091. https:\/\/doi.org\/10.1002\/j.1552-4604.1993.tb01945.x","journal-title":"J Clin Pharmacol"},{"key":"5118_CR57","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.ijpharm.2005.10.010","volume":"307","author":"DE Owens","year":"2006","unstructured":"Owens DE, Peppas NA (2006) Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm 307:93\u2013102. https:\/\/doi.org\/10.1016\/j.ijpharm.2005.10.010","journal-title":"Int J Pharm"},{"key":"5118_CR58","doi-asserted-by":"publisher","first-page":"865","DOI":"10.3797\/scipharm.1211-20","volume":"81","author":"K Pagar","year":"2013","unstructured":"Pagar K, Vavia P (2013) Rivastigmine-loaded L-lactide-depsipeptide polymeric nanoparticles: decisive formulation variable optimization. Sci Pharm 81:865\u2013885. https:\/\/doi.org\/10.3797\/scipharm.1211-20","journal-title":"Sci Pharm"},{"key":"5118_CR59","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.pharep.2016.12.002","volume":"69","author":"S Palle","year":"2017","unstructured":"Palle S, Neerati P (2017) Enhancement of oral bioavailability of rivastigmine with quercetin nanoparticles by inhibiting CYP3A4 and esterases. Pharmacol Rep 69:365\u2013370. https:\/\/doi.org\/10.1016\/j.pharep.2016.12.002","journal-title":"Pharmacol Rep"},{"key":"5118_CR60","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.nano.2005.12.003","volume":"2","author":"C Pinto Reis","year":"2006","unstructured":"Pinto Reis C, Neufeld RJ, Ribeiro AJ, Veiga F (2006) Nanoencapsulation I. methods for preparation of drug-loaded polymeric nanoparticles. Nanomed Nanotechnol Biol Med 2:8\u201321. https:\/\/doi.org\/10.1016\/j.nano.2005.12.003","journal-title":"Nanomed Nanotechnol Biol Med"},{"key":"5118_CR61","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1056\/NEJMra0909142","volume":"362","author":"HW Querfurth","year":"2010","unstructured":"Querfurth HW, LaFerla FM (2010) Mechanisms of disease Alzheimer\u2019s disease. N Engl J Med 362:329\u2013344","journal-title":"N Engl J Med"},{"key":"5118_CR62","doi-asserted-by":"publisher","unstructured":"Radwan RR, Ghaffar AMA, Ali HE (2019) Gamma radiation preparation of chitosan nanoparticles for controlled delivery of memantine. https:\/\/doi.org\/10.1177\/0885328219890071","DOI":"10.1177\/0885328219890071"},{"key":"5118_CR63","doi-asserted-by":"publisher","first-page":"89","DOI":"10.2165\/00023210-199707020-00001","volume":"7","author":"M Rainer","year":"1997","unstructured":"Rainer M (1997) Galanthamine in Alzheimer\u2019s disease. A new alternative to tacrine? CNS Drugs 7:89\u201397. https:\/\/doi.org\/10.2165\/00023210-199707020-00001","journal-title":"CNS Drugs"},{"key":"5118_CR64","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1586\/14737175.8.1.9","volume":"8","author":"G Razay","year":"2008","unstructured":"Razay G, Wilcock GK (2008) Galantamine in Alzheimer\u2019s disease. Expert Rev Neurother 8:9\u201317. https:\/\/doi.org\/10.1586\/14737175.8.1.9","journal-title":"Expert Rev Neurother"},{"key":"5118_CR65","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1056\/NEJMoa013128","volume":"348","author":"B Reisberg","year":"2003","unstructured":"Reisberg B, Doody R, St\u00f6ffler A, Schmitt F, Ferris S, M\u00f6bius HJ, Memantine Study Group (2003) Memantine in moderate-to-severe Alzheimer\u2019s disease. N Engl J Med 348:1333\u20131341. https:\/\/doi.org\/10.1056\/NEJMoa013128","journal-title":"N Engl J Med"},{"key":"5118_CR66","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s13346-012-0086-y","volume":"3","author":"B Saladini","year":"2013","unstructured":"Saladini B, Bigucci F, Cerchiara T, Gallucci MC, Luppi B (2013) Microparticles based on chitosan\/pectin polyelectrolyte complexes for nasal delivery of tacrine hydrochloride. Drug Deliv Transl Res 3:33\u201341. https:\/\/doi.org\/10.1007\/s13346-012-0086-y","journal-title":"Drug Deliv Transl Res"},{"key":"5118_CR67","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.colsurfb.2017.08.031","volume":"159","author":"S Salatin","year":"2017","unstructured":"Salatin S, Barar J, Barzegar-Jalali M, Adibkia K, Jelvehgari M (2017) Thermosensitive in situ nanocomposite of rivastigmine hydrogen tartrate as an intranasal delivery system: development, characterization, ex vivo permeation and cellular studies. Colloids Surf B: Biointerfaces 159:629\u2013638. https:\/\/doi.org\/10.1016\/j.colsurfb.2017.08.031","journal-title":"Colloids Surf B: Biointerfaces"},{"key":"5118_CR68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12951-018-0356-z","volume":"16","author":"E S\u00e1nchez-L\u00f3pez","year":"2018","unstructured":"S\u00e1nchez-L\u00f3pez E, Ettcheto M, Egea MA, Espina M, Cano A, Calpena AC, Camins A, Carmona N, Silva AM, Souto EB, Garc\u00eda ML (2018) Memantine loaded PLGA PEGylated nanoparticles for Alzheimer\u2019s disease: in vitro and in vivo characterization. J Nanobiotechnol 16:1\u201316. https:\/\/doi.org\/10.1186\/s12951-018-0356-z","journal-title":"J Nanobiotechnol"},{"key":"5118_CR69","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/s41593-018-0325-8","volume":"22","author":"M Santello","year":"2019","unstructured":"Santello M, Toni N, Volterra A (2019) Astrocyte function from information processing to cognition and cognitive impairment. Nat Neurosci 22:154\u2013166. https:\/\/doi.org\/10.1038\/s41593-018-0325-8","journal-title":"Nat Neurosci"},{"key":"5118_CR70","doi-asserted-by":"publisher","first-page":"135","DOI":"10.5958\/0974-360X.2017.00030.0","volume":"10","author":"S Sathesh Kumar","year":"2017","unstructured":"Sathesh Kumar S, Felix Joe V (2017) Pharmacokinetics of tacrine loaded MPEG-PCL polymeric nanoparticles. Res J Pharm Technol 10:135\u2013140. https:\/\/doi.org\/10.5958\/0974-360X.2017.00030.0","journal-title":"Res J Pharm Technol"},{"key":"5118_CR71","doi-asserted-by":"publisher","unstructured":"Selkoe DJ, Hardy J (2016) The amyloid hypothesis of Alzheimer\u2019s disease at 25 years. EMBO Mol Med. https:\/\/doi.org\/10.15252\/emmm.201606210","DOI":"10.15252\/emmm.201606210"},{"key":"5118_CR72","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.ejps.2015.07.002","volume":"78","author":"B Shah","year":"2015","unstructured":"Shah B, Khunt D, Bhatt H, Misra M, Padh H (2015) Application of quality by design approach for intranasal delivery of rivastigmine loaded solid lipid nanoparticles: effect on formulation and characterization parameters. Eur J Pharm Sci 78:54\u201366. https:\/\/doi.org\/10.1016\/j.ejps.2015.07.002","journal-title":"Eur J Pharm Sci"},{"key":"5118_CR73","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1159\/000106895","volume":"7","author":"Sharon","year":"1996","unstructured":"Sharon, Friedhoff LR (1996) The efficacy and safety of donepezil in patients with Alzheimer\u2019s disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. Dement Geriatr Cogn Disord 7:293\u2013303. https:\/\/doi.org\/10.1159\/000106895","journal-title":"Dement Geriatr Cogn Disord"},{"key":"5118_CR74","doi-asserted-by":"publisher","unstructured":"Silva S, Marto J, Gon\u00e7alves L, et al (2020) Formulation, characterization and evaluation against sh-sy5y cells of new tacrine and tacrine-map loaded with lipid nanoparticles. Nanomaterials 10:. https:\/\/doi.org\/10.3390\/nano10102089","DOI":"10.3390\/nano10102089"},{"key":"5118_CR75","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.yexmp.2008.12.004","volume":"86","author":"R Singh","year":"2009","unstructured":"Singh R, Lillard JW (2009) Nanoparticle-based targeted drug delivery. Exp Mol Pathol 86:215\u2013223. https:\/\/doi.org\/10.1016\/j.yexmp.2008.12.004","journal-title":"Exp Mol Pathol"},{"key":"5118_CR76","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.ejps.2013.02.013","volume":"49","author":"P Sozio","year":"2013","unstructured":"Sozio P, Cerasa LS, Laserra S, Cacciatore I, Cornacchia C, di Filippo ES, Fulle S, Fontana A, di Crescenzo A, Grilli M, Marchi M, di Stefano A (2013) Memantine-sulfur containing antioxidant conjugates as potential prodrugs to improve the treatment of Alzheimer\u2019s disease. Eur J Pharm Sci 49:187\u2013198. https:\/\/doi.org\/10.1016\/j.ejps.2013.02.013","journal-title":"Eur J Pharm Sci"},{"key":"5118_CR77","doi-asserted-by":"publisher","first-page":"28","DOI":"10.5530\/jyp.2015.1.6","volume":"7","author":"N Tamilselvan","year":"2015","unstructured":"Tamilselvan N, Raghavan CV (2015) Formulation and characterization of anti-Alzheimer\u2019s drug loaded chitosan nanoparticles and its in vitro biological evaluation. J Young Pharm 7:28\u201335. https:\/\/doi.org\/10.5530\/jyp.2015.1.6","journal-title":"J Young Pharm"},{"key":"5118_CR78","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/S0024-3205(00)00411-2","volume":"66","author":"GL Wenk","year":"2000","unstructured":"Wenk GL, Quack G, Moebius HJ, Danysz W (2000) No interaction of memantine with acetylcholinesterase inhibitors approved for clinical use. Life Sci 66:1079\u20131083. https:\/\/doi.org\/10.1016\/S0024-3205(00)00411-2","journal-title":"Life Sci"},{"key":"5118_CR79","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ejpb.2008.03.009","volume":"70","author":"B Wilson","year":"2008","unstructured":"Wilson B, Samanta MK, Santhi K et al (2008a) Targeted delivery of tacrine into the brain with polysorbate 80-coated poly(n-butylcyanoacrylate) nanoparticles. Eur J Pharm Biopharm 70:75\u201384. https:\/\/doi.org\/10.1016\/j.ejpb.2008.03.009","journal-title":"Eur J Pharm Biopharm"},{"key":"5118_CR80","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.brainres.2008.01.039","volume":"1200","author":"B Wilson","year":"2008","unstructured":"Wilson B, Samanta MK, Santhi K, Kumar KPS, Paramakrishnan N, Suresh B (2008b) Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer\u2019s disease. Brain Res 1200:159\u2013168. https:\/\/doi.org\/10.1016\/j.brainres.2008.01.039","journal-title":"Brain Res"},{"key":"5118_CR81","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.nano.2009.04.001","volume":"6","author":"B Wilson","year":"2010","unstructured":"Wilson B, Samanta MK, Santhi K, Kumar KPS, Ramasamy M, Suresh B (2010) Chitosan nanoparticles as a new delivery system for the anti-Alzheimer drug tacrine. Nanomed Nanotechnol Biol Med 6:144\u2013152. https:\/\/doi.org\/10.1016\/j.nano.2009.04.001","journal-title":"Nanomed Nanotechnol Biol Med"},{"key":"5118_CR82","doi-asserted-by":"publisher","first-page":"599","DOI":"10.4155\/tde.11.21","volume":"2","author":"B Wilson","year":"2011","unstructured":"Wilson B, Samanta MK, Muthu MS, Vinothapooshan G (2011) Design and evaluation of chitosan nanoparticles as novel drug carrier for the delivery of rivastigmine to treat Alzheimer\u2019s disease. Ther Deliv 2:599\u2013609. https:\/\/doi.org\/10.4155\/tde.11.21","journal-title":"Ther Deliv"},{"key":"5118_CR83","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1080\/21691401.2017.1394872","volume":"46","author":"M Yasir","year":"2018","unstructured":"Yasir M, Sara UVS, Chauhan I, Gaur PK, Singh AP, Puri DA (2018) Solid lipid nanoparticles for nose to brain delivery of donepezil: formulation, optimization by Box\u2013Behnken design, in vitro and in vivo evaluation. Artif Cells Nanomed Biotechnol 46:1838\u20131851. https:\/\/doi.org\/10.1080\/21691401.2017.1394872","journal-title":"Artif Cells Nanomed Biotechnol"}],"container-title":["Journal of Nanoparticle Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11051-020-05118-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11051-020-05118-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11051-020-05118-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,10]],"date-time":"2021-02-10T14:50:42Z","timestamp":1612968642000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11051-020-05118-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":83,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["5118"],"URL":"https:\/\/doi.org\/10.1007\/s11051-020-05118-9","relation":{},"ISSN":["1388-0764","1572-896X"],"issn-type":[{"type":"print","value":"1388-0764"},{"type":"electronic","value":"1572-896X"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"18 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"9"}}